Monday 6-9-2014 Glaxosmithkline Plc (GSK) $GSK ope
Post# of 51
Posted On: 06/09/2014 6:18:50 PM
Monday 6-9-2014 Glaxosmithkline Plc (GSK) $GSK opened at 53.85 hitting the high price of 53.98 and a day low of 53.70 with a total volume of 1,504,303. GSK had a previous close of 53.70 and has been seeing an average volume of 2,750,010.
Overall Average: 40% Sell
Recent stock forum discussions about GSK http://investorshangout.com/search?q=GSK&...mp;yt0=Go!
3 Stocks Crushed by the Market This Week
Keith Speights, The Motley Fool - Motley Fool - Sun Jun 08, 2:36PM CDT
The markets' rising tide didn't lift every boat this week. Some health-care stocks sprang major leaks. One of this week's big losers got hurt by the actions of its CEO. Another received a double-whammy of bad news: disappointing clinical results... (full story)
This Week in Biotech: A Trifecta of Disappointment Mars ASCO While Biogen Scores a Big Victory
Sean Williams, The Motley Fool - Motley Fool - Sat Jun 07, 12:05PM CDT
With the SPDR S&P Biotech Index up 25% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and... (full story)
Pipeline Progress at GlaxoSmithKline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 06, 10:26AM CDT
GlaxoSmithKline plc (GSK) recently announced that it has initiated a phase III study, LATITUDE-TIMI 60 on cardiovascular candidate losmapimod. (full story)
Vaccines 2014-2020: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments (Influenza, Cervical Cancer, Combinations, Hepatitis, Pneumococcal, MMR, Varicella, Poliovirus, HIB, Others)
M2 - Fri Jun 06, 8:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fm23b8/vaccines_2014) has announced the addition of the "Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments (Influenza, Cervical Cancer, Combinations, Hepatitis, Pneumococcal, MMR, Varicella, Poliovirus , HIB, Others)" report to their offering. Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments The global market for human vaccines experienced strong growth through 2013 with the introduction of new vaccines. These new products and other trends are well-covered in Vaccines: The World Market. The Kalorama information report examines the global market for vaccines, covering specifically commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable. Vaccination protects not only individuals, but also entire communities from diseases spread by person-to-person transmission. The high growth rates and successful launch of several recent products have kept interest in the global vaccine market high. This report investigates the changes vaccine manufacturers have undergone in the past year, providing world market analysis, identifying the key players, and outlining critical trends in this fast-changing industry. Included in this report are current market size and forecasts to 2020 for the following vaccines: - Pediatric Vaccines - Pneumococcal - Combinations - Varicella - MMR - Poliovirus - Hepatitis - HIB - Other Pediatric - Adult Vaccines: - Influenza - Cervical Cancer - Hepatitis - Pneumococcal - Travel; DT; Misc. Key Topics Covered: - Executive Summary - Introduction To Vaccines - Pediatric Preventive Vaccines - Adult Preventive Vaccines - Vaccines Market Summary - Issues And Trends - Company Profiles - AlphaVax, Inc. - Bavarian Nordic A/S - Baxter Healthcare - Bharat Biotech - Crucell /Johnson & Johnson - Emergent biosolutions - GlaxoSmithKline - Medimmune - Merck & Co. Inc - Novartis - Pfizer - Sanofi Pasteur For more information visit http://www.researchandmarkets.com/research/fm...cines_2014 About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. (full story)
Global Nutricosmetics Market 2014-2018
M2 - Thu Jun 05, 10:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6w6chm/global) has announced the addition of the "Global Nutricosmetics Market 2014-2018" report to their offering. The Global Nutricosmetics market will grow at a CAGR of 9.76% over the period 2013-2018. Nutricosmetics are ingestible products that help in enhancing the skin, face, body, nails, and hair of individuals. They are beauty supplements, functional foods, or beverages that contain active ingredients and nutrients such as botanical actives, sterol esters, lycopene, enzymes, proteins, minerals, and vitamins that are developed and marketed specifically as beauty aids. Their name derives from the fusion of the terms nutraceuticals and cosmeceuticals. Vendors innovate their existing products to keep up with the increased demand for nutricosmetics, to meet consumer requirements, to survive in a competitive market, and to gain more consumers. They also try to develop nutricosmetic supplements and food products with new ingredients that provide additional benefits to the skin or treat other skin issues. According to the report, one of the main drivers is the rising global aging population. This growth is resulting in an increase in the need for anti-aging, age defying, and anti-hair loss nutricosmetic products. Further, the report states that one of the main challenges hindering market growth is the lack of information and awareness about the different types of nutricosmetic products available in the market. This hampers the demand for these products. Key Vendors - Ferrosan Inc. - Functionalab Inc. - Laboratoire Oenobiol SAS - Laboratoires Inn?ov SNC Other Prominent Vendors - BASF SE - Beiersdorf AG - Borba Inc. - Carotech Bhd - Denomega Nutritional Oils AS - Frutarom Industries Ltd. - Frutels LLC - GlaxoSmithKline plc - GliSODin Skin Nutrients - Groupe Danone - Husumer Mineralbrunnem HMB GmbH & Co. K.G - IMCD Group BV - Lonza Group Ltd. - LycoRed Ltd. - Martek Biosciences Corp. - N.V. Perricone M.D. Ltd. - Nutrilo GmbH - Quest Vitamins Ltd. - Shishiedo Co. Ltd. - Solgar Inc. - Unilever Group For more information visit http://www.researchandmarkets.com/research/6w6chm/global (full story)
Rite Aid, PHH, Novartis, Pfizer and GlaxoSmithKline highlighted as Zacks Bull and Bear of the Day
PR Newswire - Thu Jun 05, 8:30AM CDT
Zacks Equity Research highlights Rite Aid Corporation (NYSE:RAD-Free Report) as the Bull of the Day and PHH Corp (NYSE
HH-Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis onNovartis (NYSE:NVS-Free Report), Pfizer (NYSE FE-Free Report) and GlaxoSmithKline (NYSE:GSK-Free Report). (full story)
Flamel Technologies Announces Intent to Resubmit Second NDA
Marketwire - Thu Jun 05, 7:02AM CDT
Flamel Technologies (NASDAQ: FLML) announced today that it has been informed by the Active Pharmaceutical Ingredient (API) supplier for its second New Drug Application (NDA) that the Food and Drug Administration (FDA) has now classified its facility as acceptable. This application had been subjected to a Complete Response Letter (CRL) on its April 28, 2014 PDUFA date, citing certain facility issues as the primary cause. Based on this information, Flamel plans to resubmit the NDA to the FDA in the very near future. The Company expects to make an announcement prior to the end of June as to whether the FDA will grant a Class 1 or Class 2 status for the resubmission. (full story)
Premature Labor (Tocolysis) - Pipeline Review, H1 2014
M2 - Thu Jun 05, 5:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/379vtk/premature_labor) has announced the addition of the "Premature Labor (Tocolysis) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Premature Labor (Tocolysis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Premature Labor (Tocolysis) and special features on late-stage and discontinued projects. This report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - GlaxoSmithKline plc - Actavis plc - Kissei Pharmaceutical Co., Ltd. - PDC Biotech GmbH - Ferring Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/37...ture_labor (full story)
AG Gansler Reaches $105M Settlement with GlaxoSmithKline Over Unlawful Promotion of Asthma Drug Advair, Other Medications Drug manufacturer must also reform pharmaceutical sales incentives
M2 - Thu Jun 05, 5:24AM CDT
Attorney General Douglas F. Gansler today announced a $105 million settlement with GlaxoSmithKline, LLC, (GSK) that promotes consumer health by changing the way pharmaceutical sales representatives are compensated. The settlement, which includes attorneys general from 45 states, resolves allegations that GSK unlawfully promoted its asthma drug, Advair, and antidepressant drugs, Paxil and Wellbutrin. (full story)
Theravance, Inc. and Theravance Biopharma, Inc. Announce Completion of Separation of Late-Stage Partnered Respiratory Assets From Biopharmaceutical Operations
Marketwire - Thu Jun 05, 1:48AM CDT
Theravance, Inc. (NASDAQ: THRX) ("Theravance"
and Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" today announced the completion of the separation of Theravance Biopharma, Inc., the research and development-based biopharmaceutical business, from Theravance, Inc. to form two, independent, publicly traded companies with differing business objectives and opportunities, via a dividend distribution of Theravance Biopharma shares to Theravance stockholders. (full story)
GlaxoSmithKline agrees to $105 million settlement
AP - Wed Jun 04, 5:39PM CDT
SAN DIEGO (AP) — GlaxoSmithKline PLC will pay $105 million to dozens of states to settle allegations that it unlawfully marketed its asthma drug Advair and the antidepressants Paxil and Wellbutrin. (full story)
Positive ASCO Updates from Novartis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 04, 4:50PM CDT
Novartis (NVS) recently presented positive results from a pivotal phase III study, PANORAMA-1, on LBH589 at the Annual Meeting of the ASCO. (full story)
How Will GlaxoSmithKline (GSK) Stock React To Settlement of Promotion Claims?
at The Street - Wed Jun 04, 4:18PM CDT
Shares of GlaxoSmithKline (GSK) are lower in after-hours trading after it was announced that the U.K. drugmaker will pay $105 million to settle claims by California, New York and over 40 other states that it illegally promoted asthma and... (full story)
Vietnam Healthcare, Regulatory and Reimbursement Landscape Report 2014
M2 - Wed Jun 04, 8:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sjgxh4/countryfocus) has announced the addition of the "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Vietnam" report to their offering. The pharmaceutical market in Vietnam is set to increase in value by $5 billion over the next six years, reaching a net worth of $8 billion by 2020 and representing an impressive CAGR of 15.4% In 2013, Vietnam's population stood at 89.7 million, an increase from 85.1 million in 2008 due to the high birth rate and low mortality rate. The country's pharmaceutical market was estimated to have been worth $2.9 billion in 2013 and is expected to reach $8 billion by 2020 at a projected Compound Annual Growth Rate (CAGR) of 15.4%. According to an EU Economic and Commercial Counsellor (EUECC) report in 2011, Vietnam's medical device market was estimated at approximately $220m in 2010 and is expected to grow at a CAGR of 10% to over $350m by 2015. The positive trends in Vietnam's healthcare market can primarily be attributed to: - Increasing coverage of healthcare insurance - Government initiatives to improve healthcare facilities Scope - Overview of the pharmaceutical and medical device markets, including size, segmentation and key drivers and barriers - Profiles and SWOT analyses of the major players in the pharmaceutical market: Sanofi, GlaxoSmithKline, AstraZeneca, Novartis and DHG Pharmaceutical JSC - An insightful review of the reimbursement and regulatory landscape, covering the healthcare reimbursement process, regulatory agencies, and the approval processes for new drugs and medical devices - Detailed analysis of the political and economic environment, including economic indicators, demographics, healthcare infrastructure and healthcare expenditure - An overview of the opportunities for and challenges to growth in the healthcare market Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Overview of the Pharmaceutical and Medical Device Markets 4 Market Access 5 Country Analysis 6 Opportunities and Challenges 7 Appendix For more information visit http://www.researchandmarkets.com/research/sj...untryfocus (full story)
World Smoking Cessation and Nicotine De-addiction Products Market 2013-2019: Nicotine Gums, Patches, Lozenges, Inhalers, Sprays, Sublingual Tablets, Zyban, Chantix/Champix, E-cigarettes
M2 - Wed Jun 04, 3:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7ppcf5/smoking_cessation) has announced the addition of the "Smoking Cessation and Nicotine De-addiction Products Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The electronic cigarettes market was valued at USD 1,662.5 million in 2012 and is expected to grow at a CAGR of 33% from 2013 to 2019, to reach an estimated value of USD 12,238.4million in 2019. Key players in the e-cigarettes market include VMR Products LLC, NJOY, Lorillard, Inc., Nicoventures and Altria Group. Electronic cigarettes is the largest and the fastest growing segment in the smoking cessation market. More than 80% of the e-cigarette market share lies with Europe and North America. Regulation of e-cigarettes as medical devices or tobacco products are still in debate. Lobbyists across the globe are trying to influence regulatory agencies to ease restrictions on e-cigarettes. Although this has not yet affected market growth, restrictions and bans on the use of e-cigarettes may adversely affect market growth in the near future. Smoking cessation products are a better alternative for tobacco and cigarette addicts. Smoking cessation products market comprises nicotine replacement therapy (NRT) products, prescription drugs and electronic cigarettes. With the rising incidences of lung cancer, and other diseases such as respiratory and cardiac disorders due to smoking, governments of various countries have started taking initiatives for controlling cigarette addiction. The U.S. Centers for Disease Control and Prevention (CDC) stated that 2011 witnessed around 44 million adults addicted to cigarette smoking in the U.S.,with majority being from the low-income class. Higher taxes on tobacco products, ban on smoking in public places, benefits and assistance for smoking cessation therapies were some of the important policies implemented in order to motivate addicts to quit smoking. Nicotine replacement therapy (NRT) products comprise nicotine gums, patches, lozenges, sprays, inhalers and sublingual tablets. All these products are available over-the-counter, except for Nicotrol nicotine inhalers and nasal sprays which are sold only with prescription. The regulations on sales of NRT products differ from country to country. Nicotine gums are the oldest products in the market and cover around 38% share of the total NRT market. The market for nicotine lozenges is expected to grow at a faster rate owing to convenient use, low cost and easy availability. Nicotine transdermal patches are the second most widely used NRT products for smoking cessation. Major players in the NRT market include GlaxoSmithKline, Novartis and Johnson & Johnson. First line drug therapy for smoking cessation includes Zyban by GlaxoSmithKline, and Chantix (Champix in countries other than the U.S.) by Pfizer. The drug therapy market has suffered from consistent criticism, as suicidal attempts were reported by patients prescribed with either of these drugs. For the same reason, sales of these drugs has been witnessing decline for the past few years. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Smoking Cessation and Nicotine De-addiction Market Overview Chapter 4 Global Smoking Cessation and Nicotine De-addiction Products Market, by Product Type Chapter 5 Global Smoking Cessation and Nicotine De-addiction Products Market, by Geography Chapter 6 Competitive Landscape Chapter 7 Recommendations Chapter 8 Company Profiles - Cipla Ltd. - GlaxoSmithKline, Inc. - Imperial Tobacco Company of India (ITC Ltd). - McNeil AB - NJOY, Inc. - Novartis International AG - Pfizer, Inc. - Revolymer PLC - Takeda Pharmaceutical Co. Ltd. - VMR Products LLC For more information visit http://www.researchandmarkets.com/research/7p..._cessation (full story)
Puma Biotech Crashes on PB272 Study News - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 03, 3:35PM CDT
Puma Biotech's (PBYI) PB272 showed moderate efficacy in a phase II study. (full story)
Why Theravance Inc.'s 22% Drop Isn't What It Appears
Sean Williams, The Motley Fool - Motley Fool - Tue Jun 03, 12:04PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Theravance , a developer of small-molecule... (full story)
Will China's Price Gouging Accusations Have Any Impact on Johnson & Johnson and Other Eye Care Compa
Rich Duprey, The Motley Fool - Motley Fool - Tue Jun 03, 9:26AM CDT
Source: Wikimedia Commons Yet another industry has run afoul of China's antitrust laws, this time seven companies in eye care that were accused of fixing prices. According to the National Development and Reform Commission, the eye care companies... (full story)
Gorman Rupp, American Vanguard, Pharmacyclics, GlaxoSmithKline andJohnson & Johnson highlighted as Zacks Bull and Bear of the Day
PR Newswire - Tue Jun 03, 8:30AM CDT
Zacks Equity Research highlights Gorman Rupp (AMEX:GRC-Free Report) as the Bull of the Day and American Vanguard (NYSE:AVD-Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis onPharmacyclics Inc. (Nasdaq CYC-Free Report), GlaxoSmithKline (NYSE:GSK-Free Report) and Johnson & Johnson (NYSE:JNJ-Free Report). (full story)
Positive Data on Novartis' LDE225 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 02, 5:10PM CDT
Novartis (NVS) announced positive results from a phase II trial, BOLT (Basal cell carcinoma Outcomes in LDE225 Trial), on pipeline candidate LDE225 (sonidegib) at the American Society of Clinical Oncology (ASCO). (full story)
Overall Average: 40% Sell
Recent stock forum discussions about GSK http://investorshangout.com/search?q=GSK&...mp;yt0=Go!
3 Stocks Crushed by the Market This Week
Keith Speights, The Motley Fool - Motley Fool - Sun Jun 08, 2:36PM CDT
The markets' rising tide didn't lift every boat this week. Some health-care stocks sprang major leaks. One of this week's big losers got hurt by the actions of its CEO. Another received a double-whammy of bad news: disappointing clinical results... (full story)
This Week in Biotech: A Trifecta of Disappointment Mars ASCO While Biogen Scores a Big Victory
Sean Williams, The Motley Fool - Motley Fool - Sat Jun 07, 12:05PM CDT
With the SPDR S&P Biotech Index up 25% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and... (full story)
Pipeline Progress at GlaxoSmithKline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 06, 10:26AM CDT
GlaxoSmithKline plc (GSK) recently announced that it has initiated a phase III study, LATITUDE-TIMI 60 on cardiovascular candidate losmapimod. (full story)
Vaccines 2014-2020: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments (Influenza, Cervical Cancer, Combinations, Hepatitis, Pneumococcal, MMR, Varicella, Poliovirus, HIB, Others)
M2 - Fri Jun 06, 8:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fm23b8/vaccines_2014) has announced the addition of the "Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments (Influenza, Cervical Cancer, Combinations, Hepatitis, Pneumococcal, MMR, Varicella, Poliovirus , HIB, Others)" report to their offering. Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments The global market for human vaccines experienced strong growth through 2013 with the introduction of new vaccines. These new products and other trends are well-covered in Vaccines: The World Market. The Kalorama information report examines the global market for vaccines, covering specifically commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable. Vaccination protects not only individuals, but also entire communities from diseases spread by person-to-person transmission. The high growth rates and successful launch of several recent products have kept interest in the global vaccine market high. This report investigates the changes vaccine manufacturers have undergone in the past year, providing world market analysis, identifying the key players, and outlining critical trends in this fast-changing industry. Included in this report are current market size and forecasts to 2020 for the following vaccines: - Pediatric Vaccines - Pneumococcal - Combinations - Varicella - MMR - Poliovirus - Hepatitis - HIB - Other Pediatric - Adult Vaccines: - Influenza - Cervical Cancer - Hepatitis - Pneumococcal - Travel; DT; Misc. Key Topics Covered: - Executive Summary - Introduction To Vaccines - Pediatric Preventive Vaccines - Adult Preventive Vaccines - Vaccines Market Summary - Issues And Trends - Company Profiles - AlphaVax, Inc. - Bavarian Nordic A/S - Baxter Healthcare - Bharat Biotech - Crucell /Johnson & Johnson - Emergent biosolutions - GlaxoSmithKline - Medimmune - Merck & Co. Inc - Novartis - Pfizer - Sanofi Pasteur For more information visit http://www.researchandmarkets.com/research/fm...cines_2014 About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. (full story)
Global Nutricosmetics Market 2014-2018
M2 - Thu Jun 05, 10:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6w6chm/global) has announced the addition of the "Global Nutricosmetics Market 2014-2018" report to their offering. The Global Nutricosmetics market will grow at a CAGR of 9.76% over the period 2013-2018. Nutricosmetics are ingestible products that help in enhancing the skin, face, body, nails, and hair of individuals. They are beauty supplements, functional foods, or beverages that contain active ingredients and nutrients such as botanical actives, sterol esters, lycopene, enzymes, proteins, minerals, and vitamins that are developed and marketed specifically as beauty aids. Their name derives from the fusion of the terms nutraceuticals and cosmeceuticals. Vendors innovate their existing products to keep up with the increased demand for nutricosmetics, to meet consumer requirements, to survive in a competitive market, and to gain more consumers. They also try to develop nutricosmetic supplements and food products with new ingredients that provide additional benefits to the skin or treat other skin issues. According to the report, one of the main drivers is the rising global aging population. This growth is resulting in an increase in the need for anti-aging, age defying, and anti-hair loss nutricosmetic products. Further, the report states that one of the main challenges hindering market growth is the lack of information and awareness about the different types of nutricosmetic products available in the market. This hampers the demand for these products. Key Vendors - Ferrosan Inc. - Functionalab Inc. - Laboratoire Oenobiol SAS - Laboratoires Inn?ov SNC Other Prominent Vendors - BASF SE - Beiersdorf AG - Borba Inc. - Carotech Bhd - Denomega Nutritional Oils AS - Frutarom Industries Ltd. - Frutels LLC - GlaxoSmithKline plc - GliSODin Skin Nutrients - Groupe Danone - Husumer Mineralbrunnem HMB GmbH & Co. K.G - IMCD Group BV - Lonza Group Ltd. - LycoRed Ltd. - Martek Biosciences Corp. - N.V. Perricone M.D. Ltd. - Nutrilo GmbH - Quest Vitamins Ltd. - Shishiedo Co. Ltd. - Solgar Inc. - Unilever Group For more information visit http://www.researchandmarkets.com/research/6w6chm/global (full story)
Rite Aid, PHH, Novartis, Pfizer and GlaxoSmithKline highlighted as Zacks Bull and Bear of the Day
PR Newswire - Thu Jun 05, 8:30AM CDT
Zacks Equity Research highlights Rite Aid Corporation (NYSE:RAD-Free Report) as the Bull of the Day and PHH Corp (NYSE
HH-Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis onNovartis (NYSE:NVS-Free Report), Pfizer (NYSE FE-Free Report) and GlaxoSmithKline (NYSE:GSK-Free Report). (full story) Flamel Technologies Announces Intent to Resubmit Second NDA
Marketwire - Thu Jun 05, 7:02AM CDT
Flamel Technologies (NASDAQ: FLML) announced today that it has been informed by the Active Pharmaceutical Ingredient (API) supplier for its second New Drug Application (NDA) that the Food and Drug Administration (FDA) has now classified its facility as acceptable. This application had been subjected to a Complete Response Letter (CRL) on its April 28, 2014 PDUFA date, citing certain facility issues as the primary cause. Based on this information, Flamel plans to resubmit the NDA to the FDA in the very near future. The Company expects to make an announcement prior to the end of June as to whether the FDA will grant a Class 1 or Class 2 status for the resubmission. (full story)
Premature Labor (Tocolysis) - Pipeline Review, H1 2014
M2 - Thu Jun 05, 5:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/379vtk/premature_labor) has announced the addition of the "Premature Labor (Tocolysis) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Premature Labor (Tocolysis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Premature Labor (Tocolysis) and special features on late-stage and discontinued projects. This report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - GlaxoSmithKline plc - Actavis plc - Kissei Pharmaceutical Co., Ltd. - PDC Biotech GmbH - Ferring Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/37...ture_labor (full story)
AG Gansler Reaches $105M Settlement with GlaxoSmithKline Over Unlawful Promotion of Asthma Drug Advair, Other Medications Drug manufacturer must also reform pharmaceutical sales incentives
M2 - Thu Jun 05, 5:24AM CDT
Attorney General Douglas F. Gansler today announced a $105 million settlement with GlaxoSmithKline, LLC, (GSK) that promotes consumer health by changing the way pharmaceutical sales representatives are compensated. The settlement, which includes attorneys general from 45 states, resolves allegations that GSK unlawfully promoted its asthma drug, Advair, and antidepressant drugs, Paxil and Wellbutrin. (full story)
Theravance, Inc. and Theravance Biopharma, Inc. Announce Completion of Separation of Late-Stage Partnered Respiratory Assets From Biopharmaceutical Operations
Marketwire - Thu Jun 05, 1:48AM CDT
Theravance, Inc. (NASDAQ: THRX) ("Theravance"
and Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" today announced the completion of the separation of Theravance Biopharma, Inc., the research and development-based biopharmaceutical business, from Theravance, Inc. to form two, independent, publicly traded companies with differing business objectives and opportunities, via a dividend distribution of Theravance Biopharma shares to Theravance stockholders. (full story) GlaxoSmithKline agrees to $105 million settlement
AP - Wed Jun 04, 5:39PM CDT
SAN DIEGO (AP) — GlaxoSmithKline PLC will pay $105 million to dozens of states to settle allegations that it unlawfully marketed its asthma drug Advair and the antidepressants Paxil and Wellbutrin. (full story)
Positive ASCO Updates from Novartis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 04, 4:50PM CDT
Novartis (NVS) recently presented positive results from a pivotal phase III study, PANORAMA-1, on LBH589 at the Annual Meeting of the ASCO. (full story)
How Will GlaxoSmithKline (GSK) Stock React To Settlement of Promotion Claims?
at The Street - Wed Jun 04, 4:18PM CDT
Shares of GlaxoSmithKline (GSK) are lower in after-hours trading after it was announced that the U.K. drugmaker will pay $105 million to settle claims by California, New York and over 40 other states that it illegally promoted asthma and... (full story)
Vietnam Healthcare, Regulatory and Reimbursement Landscape Report 2014
M2 - Wed Jun 04, 8:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sjgxh4/countryfocus) has announced the addition of the "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Vietnam" report to their offering. The pharmaceutical market in Vietnam is set to increase in value by $5 billion over the next six years, reaching a net worth of $8 billion by 2020 and representing an impressive CAGR of 15.4% In 2013, Vietnam's population stood at 89.7 million, an increase from 85.1 million in 2008 due to the high birth rate and low mortality rate. The country's pharmaceutical market was estimated to have been worth $2.9 billion in 2013 and is expected to reach $8 billion by 2020 at a projected Compound Annual Growth Rate (CAGR) of 15.4%. According to an EU Economic and Commercial Counsellor (EUECC) report in 2011, Vietnam's medical device market was estimated at approximately $220m in 2010 and is expected to grow at a CAGR of 10% to over $350m by 2015. The positive trends in Vietnam's healthcare market can primarily be attributed to: - Increasing coverage of healthcare insurance - Government initiatives to improve healthcare facilities Scope - Overview of the pharmaceutical and medical device markets, including size, segmentation and key drivers and barriers - Profiles and SWOT analyses of the major players in the pharmaceutical market: Sanofi, GlaxoSmithKline, AstraZeneca, Novartis and DHG Pharmaceutical JSC - An insightful review of the reimbursement and regulatory landscape, covering the healthcare reimbursement process, regulatory agencies, and the approval processes for new drugs and medical devices - Detailed analysis of the political and economic environment, including economic indicators, demographics, healthcare infrastructure and healthcare expenditure - An overview of the opportunities for and challenges to growth in the healthcare market Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Overview of the Pharmaceutical and Medical Device Markets 4 Market Access 5 Country Analysis 6 Opportunities and Challenges 7 Appendix For more information visit http://www.researchandmarkets.com/research/sj...untryfocus (full story)
World Smoking Cessation and Nicotine De-addiction Products Market 2013-2019: Nicotine Gums, Patches, Lozenges, Inhalers, Sprays, Sublingual Tablets, Zyban, Chantix/Champix, E-cigarettes
M2 - Wed Jun 04, 3:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7ppcf5/smoking_cessation) has announced the addition of the "Smoking Cessation and Nicotine De-addiction Products Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The electronic cigarettes market was valued at USD 1,662.5 million in 2012 and is expected to grow at a CAGR of 33% from 2013 to 2019, to reach an estimated value of USD 12,238.4million in 2019. Key players in the e-cigarettes market include VMR Products LLC, NJOY, Lorillard, Inc., Nicoventures and Altria Group. Electronic cigarettes is the largest and the fastest growing segment in the smoking cessation market. More than 80% of the e-cigarette market share lies with Europe and North America. Regulation of e-cigarettes as medical devices or tobacco products are still in debate. Lobbyists across the globe are trying to influence regulatory agencies to ease restrictions on e-cigarettes. Although this has not yet affected market growth, restrictions and bans on the use of e-cigarettes may adversely affect market growth in the near future. Smoking cessation products are a better alternative for tobacco and cigarette addicts. Smoking cessation products market comprises nicotine replacement therapy (NRT) products, prescription drugs and electronic cigarettes. With the rising incidences of lung cancer, and other diseases such as respiratory and cardiac disorders due to smoking, governments of various countries have started taking initiatives for controlling cigarette addiction. The U.S. Centers for Disease Control and Prevention (CDC) stated that 2011 witnessed around 44 million adults addicted to cigarette smoking in the U.S.,with majority being from the low-income class. Higher taxes on tobacco products, ban on smoking in public places, benefits and assistance for smoking cessation therapies were some of the important policies implemented in order to motivate addicts to quit smoking. Nicotine replacement therapy (NRT) products comprise nicotine gums, patches, lozenges, sprays, inhalers and sublingual tablets. All these products are available over-the-counter, except for Nicotrol nicotine inhalers and nasal sprays which are sold only with prescription. The regulations on sales of NRT products differ from country to country. Nicotine gums are the oldest products in the market and cover around 38% share of the total NRT market. The market for nicotine lozenges is expected to grow at a faster rate owing to convenient use, low cost and easy availability. Nicotine transdermal patches are the second most widely used NRT products for smoking cessation. Major players in the NRT market include GlaxoSmithKline, Novartis and Johnson & Johnson. First line drug therapy for smoking cessation includes Zyban by GlaxoSmithKline, and Chantix (Champix in countries other than the U.S.) by Pfizer. The drug therapy market has suffered from consistent criticism, as suicidal attempts were reported by patients prescribed with either of these drugs. For the same reason, sales of these drugs has been witnessing decline for the past few years. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Smoking Cessation and Nicotine De-addiction Market Overview Chapter 4 Global Smoking Cessation and Nicotine De-addiction Products Market, by Product Type Chapter 5 Global Smoking Cessation and Nicotine De-addiction Products Market, by Geography Chapter 6 Competitive Landscape Chapter 7 Recommendations Chapter 8 Company Profiles - Cipla Ltd. - GlaxoSmithKline, Inc. - Imperial Tobacco Company of India (ITC Ltd). - McNeil AB - NJOY, Inc. - Novartis International AG - Pfizer, Inc. - Revolymer PLC - Takeda Pharmaceutical Co. Ltd. - VMR Products LLC For more information visit http://www.researchandmarkets.com/research/7p..._cessation (full story)
Puma Biotech Crashes on PB272 Study News - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 03, 3:35PM CDT
Puma Biotech's (PBYI) PB272 showed moderate efficacy in a phase II study. (full story)
Why Theravance Inc.'s 22% Drop Isn't What It Appears
Sean Williams, The Motley Fool - Motley Fool - Tue Jun 03, 12:04PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Theravance , a developer of small-molecule... (full story)
Will China's Price Gouging Accusations Have Any Impact on Johnson & Johnson and Other Eye Care Compa
Rich Duprey, The Motley Fool - Motley Fool - Tue Jun 03, 9:26AM CDT
Source: Wikimedia Commons Yet another industry has run afoul of China's antitrust laws, this time seven companies in eye care that were accused of fixing prices. According to the National Development and Reform Commission, the eye care companies... (full story)
Gorman Rupp, American Vanguard, Pharmacyclics, GlaxoSmithKline andJohnson & Johnson highlighted as Zacks Bull and Bear of the Day
PR Newswire - Tue Jun 03, 8:30AM CDT
Zacks Equity Research highlights Gorman Rupp (AMEX:GRC-Free Report) as the Bull of the Day and American Vanguard (NYSE:AVD-Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis onPharmacyclics Inc. (Nasdaq
CYC-Free Report), GlaxoSmithKline (NYSE:GSK-Free Report) and Johnson & Johnson (NYSE:JNJ-Free Report). (full story) Positive Data on Novartis' LDE225 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 02, 5:10PM CDT
Novartis (NVS) announced positive results from a phase II trial, BOLT (Basal cell carcinoma Outcomes in LDE225 Trial), on pipeline candidate LDE225 (sonidegib) at the American Society of Clinical Oncology (ASCO). (full story)
(0)
(0)GlaxoSmithKline PLC (GSK) Stock Research Links
Scroll down for more posts ▼